TFTom Fowler

Tom Fowler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tom Fowler has a total of 463 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of a multi-day testing approach with lateral flow devices for SARS-CoV-2

    by Tom Fowler, Sarah Tunkel, David Chapman, Raghavendran Kulasegaran-Shylini, Matthias E. Futschik, Peter Marks, Chris Kenny, Penny Bevan, Vineta Bhalla, Jeanette Hall, et al.

  • Open Access

    An umbrella protocol for the clinical evaluation of diagnostics in infectious disease

    by Edward Blandford, Sarah Tunkel, Elizabeth Coates, Carolina R Arevalo, Simon E Kolstoe, Obaghe Edeghere, Fiona Maleady-Crowe, David Chapman, Carolyn Lewis, Raghavendran Kulasegaran-Shylini, et al.

    Umbrella protocols have recently come to be widely used in clinical trial designs. However, the value of this approach in public health is less well recognized. The coronavirus disease 2019 (COVID-19) pandemic highlighted the need for rapid, reliable and scalable evaluation of diagnostic technologies. In the United Kingdom of Great Britain and Northern Ireland, this need prompted the development of an umbrella research protocol enabling multiple clinical evaluation studies of similar designs to be undertaken under a single overarching preapproved ethics and governance framework. We describe the development, implementation and evolution of this protocol, which was designed to support timely assessment of the performance of in vitro diagnostic devices and associated testing approaches in various settings. The umbrella protocol allowed studies to be started quickly during the pandemic, reduced administrative burdens, supported regulatory submissions and enabled prospective collection of samples for surveillance. While the system described reflects British governance structures, the principles underpinning this approach, including proportionality (ensuring oversight requirements are appropriate to the risk level), standardization and preapproved flexibility, are applicable to many settings. The protocol now forms part of the United Kingdom’s wider pandemic preparedness structure and illustrates how preapproved, adaptable research frameworks can accelerate evidence generation during outbreaks. The world is now assessing lessons from the COVID-19 pandemic and it is timely to consider how research systems can support innovative designs such as umbrella protocols. We therefore summarize lessons learnt and practical considerations to support other countries seeking to adopt similar approaches within their own ethical and regulatory systems.


  • Open Access

    Whole genome sequence meta-analyses reveal common and rare genetic associations with critical COVID-19

    by Athanasios Kousathanas, Konrad Rawlik, Erola Pairo-Castineira, Fiona Griffiths, Wilna Oosthuyzen, Sara Clohisey Hendry, Tomas Malinauskas, Guillaume Butler-Laporte, Prabhu Arumugam, Colin Begg, et al.

    In susceptible patients, COVID-19 causes life-threatening disease driven by immune-mediated inflammatory lung injury. We have previously shown that multiple common host genetic variants are significantly associated with susceptibility to critical Covid-19, 1;2;3 and in one case, we demonstrated that such variants can inform development of new, effective drug treatment 1;4 . Here we report an association analysis of whole-genome sequences (WGS) from 11,423 cases from the GenOMICC study and 60,628 controls, together with meta-analyses with available genome-wide data (Fig. 1). We identify a rare association signal at SLC50A1 , primarily driven by a missense variant rs147850817 (1:155138217:G:T, Arg201Leu) that may interfere with transport function, and we identify four common association signals near ARF1, ZNF462, KLF13 and MVP genes. Finally, we build a WGS-derived polygenic risk score (PRS) for critical Covid-19, which offers only marginal improvement in risk estimation for the general population but may provide clinically-valuable discrimination for extreme susceptibility.

  • Open Access

    Climate change and diagnostic samples - Opening Pandora's (post) box

    by Paul Klapper, Raghavendran Kulasegaran-Shylini, Andrew Dodgson, Malur Sudhanva, Edward Blandford, Sarah Tunkel, Sue Hill, Susan Hopkins, Tom Fowler

  • Evaluation of SARS-CoV-2 lateral flow device sensitivity: a comparison of systematic laboratory assessments with manufacturer-reported sensitivity

    by Raghavendran Kulasegaran-Shylini, Abbie Bown, Tom Collinge, Alex Sienkiewicz, David W. Eyre, Derrick Crook, Ann Sarah Walker, John Bell, Deborah A. Williamson, Isabel Oliver, et al.

  • Open Access

    Social behaviours and contact patterns across the 2020/21, 2021/22 and 2022/23 winter seasons in the UK, and associations with symptoms

    by Elisabeth Dietz, Emma Pritchard, David W. Eyre, Tim Peto, Nicole Stoesser, Philippa Matthews, Tom Fowler, Conall Watson, Thomas House, Koen B. Pouwels, et al.

    The SARS-CoV-2 pandemic had a large impact on social mixing in the UK. This study analysed data from the Office for National Statistics Coronavirus Infection Survey to examine changes in contact patterns and self-reported symptoms through three winter seasons from 2020 to 2023. Using Generalised Additive Models, we estimated levels of various contacts over time, accounting for age, sex, ethnicity, and deprivation percentile, and compared these to trends in self-reported symptoms. Our estimates indicated steady increases in physical contacts from quarter-4 2020 to the end of the study in quarter-1 2023, with notable variation in age-specific trends. School closures and holiday periods had substantial impacts on contact patterns, particularly for children. Prevalence of reported symptoms also increased steadily over time, but varied much more within-season than most contacts; specifically, the relative increase in respiratory symptom prevalence during winter peaks between seasons was much larger than increases in contacts. Our estimates also suggested that while age played a crucial role in both contact patterns and symptom reporting, the effects of deprivation were less clear and far smaller. Our findings provide insights into changes in behaviours and symptoms during the pandemic, which may help inform future public health policy and infection modelling.


  • Key SARS-CoV-2 testing strategies implemented in the UK: rationale and impact

    by Tom Fowler, Chris Kenny, Sarah Tunkel, Andrew Dodgson, Jeanette Hall, Peter Marks, Paul Klapper, Malur Sudhanva, Raghavendran Kulasegaran-Shylini, Zareen Thorlu-Bangura, et al.


  • Open Access

    Multiplex lateral flow test sensitivity and specificity in detecting influenza A, B and SARS-CoV-2 in adult patients in a UK emergency department

    by Rahul Batra, Edward Blandford, Raghavendran Kulasegaran-Shylini, Matthias E Futschik, Abbie Bown, Matthew Catton, Hermione Conti-Frith, Alexandra Alexandridou, Rebecca Gill, Clara Milroy, et al.

    Background Rapid identification of individuals with acute respiratory infections is crucial for preventing nosocomial infections. For rapid diagnosis, especially in EDs, lateral flow devices (LFDs) are a convenient, inexpensive option with a rapid turnaround. Several ‘multiplex’ LFDs (M-LFDs) now exist, testing for multiple pathogens from a single swab sample. We evaluated the real-world performance of M-LFD versus PCR testing in detecting influenza A, B and SARS-CoV-2) in the ED setting. Methods After preliminary evaluation of an M-LFD (SureScreen) with laboratory-grown virus and PCR-negative clinical samples, it was evaluated in a real-world setting at the ED of St Thomas’ Hospital (London, UK) from 1 December 2022 to 21 April 2023. Eligible participants were ≥18 years of age, admitted with respiratory symptoms and received concurrent M-LFD and PCR tests. Main endpoints were sensitivity to detect influenza A/B (primary) and SARS-CoV-2 (secondary) versus PCR. The probability of a true positive in relation to viral concentration (expressed as PCR cycle threshold (Ct)) was analysed using logistic regression. Results In total, 808 symptomatic participants were included (49.8% female; mean age 46.9 years). Test sensitivity (95% CI) was 67.0% (56.9% to 76.1%) for influenza A (n=100), 94.1% (71.3% to 99.9%) for influenza B (n=17) and 48.2% (39.7% to 56.8%) for SARS-CoV-2 (n=141). Sensitivity for SARS-CoV-2 was significantly lower than that for influenza A and B (p=0.0057 and p=0.00088, respectively). The probability of a true positive was 98% for CtConclusion The real-world performance of SureScreen M-LFD was consistent with laboratory evaluation and achieved a high sensitivity for individuals with high viral concentration, most likely to be infectious. Given the representative UK population sample, results could be generalised for use in other settings.


  • Open Access

    Effectiveness and user experience of nose and throat swabbing techniques for SARS-CoV-2 detection: results from the UK COVID-19 National Testing Programme

    by Matthias E. Futschik, Raghavendran Kulasegaran-Shylini, Edward Blandford, Sean Harper, David Chapman, Elena Turek, Somya Agrawal, Valerie Phillips, Hannah Fordham, Lee Chan, et al.

    Background: The UK’s National Health Service Test and Trace (NHSTT) program aimed to provide the most effective and accessible SARS-CoV-2 testing approach possible. Early user feedback indicated that there were accessibility issues associated with throat swabbing. We report the results of service evaluations performed by NHSTT to assess the effectiveness and user acceptance of swabbing approaches, as well as qualitative findings of user experiences from research reports, surveys, and incident reports. Our intent is to present and summarize our findings about the application of alternative swabbing approaches during the COVID-19 pandemic in the UK. Methods: From May 2020 to December 2021, NHSTT conducted a series of service evaluations assessing self-swabbing and assisted swabbing of the nose and throat, and nose only (anterior nares/mid-turbinate) using polymerase chain reaction (PCR) and lateral flow devices (LFDs), for diagnostic suitability within the COVID-19 National Testing Programme. Outcomes included observational user feedback on swabbing approaches and quantitative testing performance (concordance, sensitivity, and specificity). A post-hoc indirect comparison of swabbing approaches was also performed. Additionally, an analysis of existing cross-service research was conducted in April 2021 to determine user feedback regarding swabbing approaches. Results: Observational data from cross-service research indicated a user preference for nose swabbing over throat swabbing. Significantly more users reported that nose swabbing was easier to perform than throat swabbing (50% vs. 12%) and there were significantly fewer reported incidents. In the service evaluations, while there was reduced sensitivity for nose-only swabbing for PCR (88%) compared with nose and throat swabbing, similar sensitivities were observed for nose-only and nose and throat swabbing for LFDs. The sensitivity of nose-only swabbing for LFDs was higher for individuals with higher viral concentrations. Conclusions: User experience analyses supported a preference for nose-only swabbing. Nose-only swabbing for LFDs provided sufficient diagnostic accuracy, supporting its use as a viable option in the COVID-19 National Testing Programme. Less invasive swabbing approaches are important to maximize testing accessibility and alongside other behavioral interventions, increase user uptake.


  • Open Access

    Comparative evaluation of swabbing sites for Omicron variant detection in PCR testing

    by Tom Fowler, Edward Blandford, David Chapman, Matthias E. Futschik, Raghavendran Kulasegaran-Shylini, Sarah Tunkel, Carolyn Lewis, Alasdair Fellows, Ellie Sheppard, Leanne McCabe, et al.